Urovant Sciences Ltd – NASDAQ:UROV

Add to watchlist

$16.235

-0.00

-0.03%

Market closed

Open in 2 days

+0.43%

month

+1.06%

quarter

+62.89%

year

Market Cap	531.75M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-3.79

Revenue	N/A
EBITDA	-117.68M
Income	-116.95M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Urovant Sciences Ltd (NASDAQ:UROV): Profit margin
Mar 2020	0	-51.26M
Jun 2020	0	-30.49M
Sep 2020	0	-35.15M
Dec 2020	0	-46.79K

Urovant Sciences Ltd (NASDAQ:UROV): Earnings per share (EPS)
2020-06-18	-1.25	-1.68
2020-08-13	-1.39	-0.99
2020-11-02	-1.5	-1.12
2021-02-12	-1.59	-1.46

Urovant Sciences Ltd (NASDAQ:UROV): Debt to assets
Mar 2020	63295000	121.30M	191.64%
Jun 2020	78137000	163.07M	208.7%
Sep 2020	91457000	204.50M	223.61%
Dec 2020	100054000	254.50M	254.37%

Urovant Sciences Ltd (NASDAQ:UROV): Cash Flow
Mar 2020	-31.55M	-37K	-48.91M
Jun 2020	-30.8M	-104K	42.53M
Sep 2020	-32.64M	-344K	45.92M
Dec 2020	-110.26M	-1.32M	44.60M

Urovant Sciences Ltd
Insider Trading

Urovant Sciences Ltd (NASDAQ:UROV): Insider trades (number of shares)
Period	Buy	Sel
May 2019	545959	0
Jun 2019	704792	0
Dec 2019	0	22980013
Feb 2020	103250	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	19 Feb 2020	SUMITOMO CHEMICAL CO., LTD. other: See Footnote (1) other: See Footnote (1)	Common Stock	103,250	N/A	N/A
Option	19 Feb 2020	SMITH BRYAN E. officer: GC/Urovant Sciences, Inc. officer: GC/Urovant Sciences, I..	Stock Option (Right to Buy)	50,000	N/A	N/A
Option	19 Feb 2020	SMITH BRYAN E. officer: GC/Urovant Sciences, Inc. officer: GC/Urovant Sciences, I..	Common Shares	50,000	N/A	N/A
Option	19 Feb 2020	KATKIN KEITH director, officer: PEO;CEO/Urovant Sciences, .. director, officer: PEO;CEO/Urov..	Stock Option (Right to Buy)	180,000	N/A	N/A
Option	19 Feb 2020	KATKIN KEITH director, officer: PEO;CEO/Urovant Sciences, .. director, officer: PEO;CEO/Urov..	Common Shares	180,000	N/A	N/A
Sale	27 Dec 2019	ROIVANT SCIENCES LTD. 10 percent owner 10 percent owner	Common Shares, par value $0.000037453 per share	22,860,013	N/A	N/A
Option	9 Dec 2019	KATKIN KEITH director, officer: PEO;CEO/Urovant Sciences, .. director, officer: PEO;CEO/Urov..	Stock Option (Right to Buy)	120,000	N/A	N/A
Sale	9 Dec 2019	KATKIN KEITH director, officer: PEO;CEO/Urovant Sciences, .. director, officer: PEO;CEO/Urov..	Common Shares	120,000	N/A	N/A
Option	9 Dec 2019	KATKIN KEITH director, officer: PEO;CEO/Urovant Sciences, .. director, officer: PEO;CEO/Urov..	Common Shares	120,000	N/A	N/A
Purchase	19 Jun 2019	DEXXON HOLDINGS LTD. other: See remarks other: See remarks	Common Shares	4,957	N/A	N/A

UROV insider trading transactions

Urovant Sciences Ltd
Earnings Call Transcripts

Quarter	Transcript
Q2 2020 2 Nov 2020	Q2 2020 Earnings Call Transcript
Q1 2020 13 Aug 2020	Q1 2020 Earnings Call Transcript
Q4 2019 19 Jun 2020	Q4 2019 Earnings Call Transcript
Q3 2019 14 Feb 2020	Q3 2019 Earnings Call Transcript

UROV earnings call transcripts

Urovant Sciences Ltd
Latest News

Friday, 13 May 2022
14:18	Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo	Benzinga

Frequently Asked Questions (FAQ)

What's the price of Urovant Sciences Ltd stock today?

One share of Urovant Sciences Ltd stock can currently be purchased for approximately $16.24.
When is Urovant Sciences Ltd's next earnings date?

Unfortunately, Urovant Sciences Ltd's (UROV) next earnings date is currently unknown.
Does Urovant Sciences Ltd pay dividends?

No, Urovant Sciences Ltd does not pay dividends.
How much money does Urovant Sciences Ltd make?

Urovant Sciences Ltd has a market capitalization of 531.75M. Urovant Sciences Ltd made a loss 146.75M US dollars in net income (profit) last year or -$1.46 on an earnings per share basis.
What is Urovant Sciences Ltd's stock symbol?

Urovant Sciences Ltd is traded on the NASDAQ under the ticker symbol "UROV".
What is Urovant Sciences Ltd's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Urovant Sciences Ltd?

Shares of Urovant Sciences Ltd can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Urovant Sciences Ltd have?

Urovant Sciences Ltd employs 70 workers.
When Urovant Sciences Ltd went public?

Urovant Sciences Ltd is publicly traded company for more then 6 years since IPO on 27 Sep 2018.
What is Urovant Sciences Ltd's official website?

The official website for Urovant Sciences Ltd is urovant.com.
Where are Urovant Sciences Ltd's headquarters?

Urovant Sciences Ltd is headquartered at 5281 California Ave Ste 100, Irvine, CALIFORNIA.
How can i contact Urovant Sciences Ltd?

Urovant Sciences Ltd's mailing address is 5281 California Ave Ste 100, Irvine, CALIFORNIA and company can be reached via phone at +1 949 226 6029.

Urovant Sciences Ltd

urovant.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which through its subsidiaries, engages in the development and commercialization of therapies for urologic conditions. The company is headquartered in Irvine, California and currently employs 39 full-time employees. The firm is focused on developing and commercializing therapies for urologic conditions. Its product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist. is focused on evaluating vibegron in its over 1,400 patients, pivotal phase-3 clinical trial for the treatment of overactive bladder (OAB). The Company’s subsidiaries include Urovant Sciences, Inc., Urovant Holdings Limited, and Urovant Sciences GmbH.

+1 949 226 6029

5281 California Ave Ste 100
Irvine, CALIFORNIA

CIK: 0001740547
ISIN: BMG9381B1081
CUSIP: G9381B108